Compare Manchester United PLC (MANU) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Manchester United PLC trades at $20.68 (market cap $3.55B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Manchester United PLC is far larger — about 3.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Manchester United PLC pays a 1.26% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MANU | MRVI | |
|---|---|---|
Market Cap | $3.55B | $977.37M |
Volume | 311,271 | 2,742,564 |
Sector | Media | Health |
52-Week High | $24.19 | $9.00 |
52-Week Low | $15.20 | $2.83 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $4.38B | $1.08B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $21.08, up 1.2% with a bullish technical signal despite negative profitability metrics. The stock shows mixed earnings performance with recent beats but negative net income margins. Revenue reached $666.51M in 2025, though the company continues to post losses. Analyst sentiment is divided with 40% buy ratings, while technical indicators suggest potential near-term support at $21.
The investment case hinges on franchise valuation upside versus operational challenges. While trading at a discount to Forbes' $7.2B valuation estimate, persistent losses and high debt levels present significant risks. Champions League qualification offers revenue potential, but profitability remains elusive amid competitive pressures in European football.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
